Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.49 |
| ▸ | HTR2C | P28335 | 6/20 | 0.49 |
| ▸ | HTR2B | P41595 | 5/20 | 0.49 |
| ▸ | HTR1A | P08908 | 5/20 | 0.49 |
| ▸ | HTR6 | P50406 | 5/20 | 0.48 |
| ▸ | HTR1D | P28221 | 7/20 | 0.46 |
| ▸ | HTR1B | P28222 | 6/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.46 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.46 |
| ▸ | HTR3B | O95264 | 2/20 | 0.46 |
| ▸ | HTR1E | P28566 | 2/20 | 0.46 |
| ▸ | HTR1F | P30939 | 2/20 | 0.46 |
| ▸ | HTR7 | P34969 | 2/20 | 0.46 |
| ▸ | HTR3A | P46098 | 2/20 | 0.46 |
| ▸ | HTR5A | P47898 | 2/20 | 0.46 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.46 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.46 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.46 |
| ▸ | MPO | P05164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7023700 | 0.98 | HTR2A (0.48) | HTR2AHTR2CHTR2BHTR1AHTR6 | |
| SCHEMBL25030272 | 0.82 | MPO (0.51) | HTR2AHTR2CHTR2BHTR1AHTR6 | |
| SCHEMBL7017274 | 0.81 | ADORA2A (0.39) | HTR2ASLC6A4 | |
| SCHEMBL6364085 | 0.80 | KDM4E (0.50) | HTR2AHTR2CHTR1AHTR1DHTR1B | |
| SCHEMBL7017267 | 0.80 | ADORA2A (0.39) | HTR2AHTR2CSLC6A4 | |
| SCHEMBL6359455 | 0.74 | GPR84 (0.63) | HTR2AHTR2CHTR2BHTR1AHTR6 | |
| SCHEMBL30886870 | 0.74 | GPR84 (0.63) | HTR2AHTR2CHTR2BHTR1AHTR6 | |
| Hydrochloric Acid SCHEMBL4869205 | 0.73 | GPR84 (0.61) | HTR2AHTR2CHTR2BHTR1AHTR6 | |
| SCHEMBL7854851 | 0.71 | SLC6A4 (0.83) | HTR2AHTR2CHTR2BHTR1AHTR6 | |
| SCHEMBL20769706 | 0.71 | ADORA2A (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250806-A1 | Nicotinic acetylcholine receptor antagonists in the treatment of restless legs syndrome | PFIZER INC | 2005-11-10 | — | — | US | claimed |
| US-20030134844-A1 | Nicontinic acetylcholine receptor antagonists in the treatment of restless legs syndrome | PFIZER INC. | 2003-07-17 | — | — | US | claimed |
| EP-1178045-B1 | Azaindole-ethylamine derivatives as nicotine acetylchlorine receptor binding agents | PFIZER (US) | 2003-05-28 | — | — | EP | claimed |
| EP-1178045-A1 | Azaindole-ethylamine derivatives as nicotine acetylchlorine receptor binding agents | PFIZER INC. (US) | 2002-02-06 | — | — | EP | claimed |
| EP-0870768-A1 | Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents | PFIZER INC. (US) | 1998-10-14 | — | — | EP | claimed |
| US-20050250806-A1 | Nicotinic acetylcholine receptor antagonists in the treatment of restless legs syndrome | PFIZER INC | 2005-11-10 | — | — | US | disclosed |
| CN-1568184-A | Use of nicotinic acetylcholine receptor agonists for the treatment of restless legs syndrome | PFIZER (US) | 2005-01-19 | — | — | CN | disclosed |
| EP-1439836-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS IN THE TREATMENT OF RESTLESS LEGS SYNDROME | Pfizer Products Inc. (US) | 2004-07-28 | — | — | EP | disclosed |
| US-20030134844-A1 | Nicontinic acetylcholine receptor antagonists in the treatment of restless legs syndrome | PFIZER INC. | 2003-07-17 | — | — | US | disclosed |
| EP-1178045-B1 | Azaindole-ethylamine derivatives as nicotine acetylchlorine receptor binding agents | PFIZER (US) | 2003-05-28 | — | — | EP | disclosed |
| WO-2003037329-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS IN THE TREATMENT OF RESTLESS LEGS SYNDROME | PFIZER PRODUCTS INC. (US) | 2003-05-08 | — | — | WO | disclosed |
| EP-1178045-A1 | Azaindole-ethylamine derivatives as nicotine acetylchlorine receptor binding agents | PFIZER INC. (US) | 2002-02-06 | — | — | EP | disclosed |
| US-5977131-A | Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents | PFIZER INC. (US) | 1999-11-02 | — | — | US | disclosed |
| EP-0870768-A1 | Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents | PFIZER INC. (US) | 1998-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134844-A1 | Nicontinic acetylcholine receptor antagonists in the treatment of restless legs syndrome | CHRNA5, CHRNA1, CHRNA7 | HTR2A 255/4885HTR2C 415/4885HTR2B 179/4885 |
| US-20050250806-A1 | Nicotinic acetylcholine receptor antagonists in the treatment of restless legs syndrome | CHRNA5, CHRNA1, CHRNA2 | HTR2A 114/4885HTR2C 202/4885HTR2B 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.